Kaji Sritharan is a Consultant Vascular Surgeon in Liverpool. She qualified in 2001, and undertook her higher surgical training in London, with endovascular fellowships in Brisbane, Australia and Bad-Krozingen, Germany. She is a council member of the Vascular Society of Great Britain & Ireland and Honorary Secretary of the Venous Forum, Royal Society of Medicine. She has an interest in CLTI and performed the first LimFlow case in the UK.

Dr. Matthew Menard graduated summa cum laude, phi beta kappa and with departmental high honors from Middlebury College. He attended Harvard Medical School and received his general surgery training at the Massachusetts General Hospital and vascular surgery fellowship training at the Brigham and Women’s Hospital.  He is currently Co-Director of Endovascular Surgery and the Vascular and Endovascular Surgery Fellowship Director at the Brigham and Women’s Hospital and is an Associate Professor of Surgery at Harvard Medical School. His clinical practice spans the gamut of vascular surgical disease, with a focus on chronic limb threatening ischemia (CLTI) and complex wound care.

Dr. Menard conceived and was a National Principal Investigator of the BEST-CLI Trial, an NIH-sponsored and FDA-endorsed randomized controlled trial comparing treatment efficacy, functional outcomes, cost and cost-effectiveness associated with open surgery vs endovascular therapy for patients with CLTI. The results were recently presented at the American Heart Association and published in the New England Journal of Medicine.

Professor Andrew Bradbury has been Sampson Gamgee Professor of Vascular Surgery, University of Birmingham, and Honorary Consultant Vascular Surgeon at Heart of England (now University Hospitals Birmingham) NHS Foundation Trust, since January 2000. Andrew trained in Scotland and London and was an academic Consultant Vascular Surgeon in Edinburgh for almost 5 years before being appointed in Birmingham. Andrew completed an MBA in 2005 and was Education Dean at Birmingham Medical School for almost 5 years. Andrew was Chair the NICE Abdominal Aortic Aneurysm (AAA) national Guideline Committee (GC) and had previously worked with NICE to produce UK national guidelines on PAD and lower limb venous disease. Andrew was Co-Editor, representing the WFVS, of the Global Vascular Guidelines (GVG) on Chronic Limb Threatening Ischaemia (CLTI), which were published in JVS and EJVES in 2019. Andrew is the Chief Investigator for the UK NIHR HTA funded BASIL 2 and BASIL 3 trials. BASIL-2 results were published in the Lancet in April 2023. BASIL-3 will be published in Q2 of 2024.